Business Wire

SMOKE FREE SWEDEN: DANSKE RESTRIKTIONER PÅ NIKOTINPOSER VIL FÅ 150.000 TIL AT VENDE TILBAGE TIL RYGNING

6.10.2024 17:00:00 CEST | Business Wire | Pressemeddelelse

Del

Et foreslået forbud mod ni ud af ti nikotinposer i Danmark vil være et massivt tilbageskridt i kampen mod tobak og vil tvinge titusindvis af tidligere rygere tilbage til dødelige cigaretter, advarer førende internationale eksperter i dag.

Reguleringer på sundhedsområdet, som vil blive fremlagt for Folketinget fredag den 11. oktober, vil begrænse nikotinniveauet i en nikotinpose til 9 mg – langt under internationale standarder og kun en brøkdel af nikotinniveauet i cigaretter.

Dr. Delon Human, en global ekspert i skadereduktion og leder af ”Smoke Free Sweden”, siger: "Nikotinposer er bevist at være et langt sikrere alternativ til cigaretter og hjælper millioner af rygere med at stoppe over hele verden.”

"Forslaget, som Folketinget skal behandle, vil forbyde 90 % af de poser, der aktuelt bruges i Danmark, hvilket efterlader rygerne med valget mellem de få tilbageværende poser eller cigaretter, der indeholder 85 % mere nikotin.

"Det er ikke svært at forudsige, hvilket valg de vil ende med at træffe. Rygere, der overvejer at stoppe, vil blive nægtet et levedygtigt og sikrere alternativ, mens størstedelen af de 153.000 nuværende brugere af nikotinposer vil blive presset tilbage til cigaretter.

"At gøre den farligste måde at indtage nikotin på til den mest attraktive er simpelthen ulogisk og et massivt tilbageskridt i den fortsatte kamp mod tobakkens dødelige konsekvenser."
Danmarks naboland Sverige har vist, at en progressiv tilgang til skadesreducerende røgfrie nikotinprodukter er den bedste vej til at udrydde rygning og de sundhedskonsekvenser, som følger med.

Sverige har oplevet et ekstraordinært fald i antallet af rygere på 55 % over det seneste årti og er på nippet til officielt at blive erklæret røgfrit efter WHO’s målsætning. Sammenlignet med resten af EU har Sverige nu 44 % færre tobaksrelaterede dødsfald og en 41 % lavere kræftrate.
Sveriges succes tilskrives den udbredte brug af orale nikotinprodukter med forskellige nikotinstyrker og smagsvarianter samt regeringens politik med at lægge højere afgifter på cigaretter end på røgfrie nikotinprodukter.

Det danske forslag har til hensigt at forbyde de lange cigaretter, som i øjeblikket bruges af en tredjedel af rygerne, samtidig med at nikotinindholdet i poser begrænses.
"Forbuddet mod 30 % af cigaretterne på markedet burde være en stor mulighed for at opmuntre rygere til at skifte til sikrere alternativer som nikotinposer," siger Dr. Human. "I stedet forsøger forslagene at gøre poser ineffektive og mindre tiltalende end cigaretter.

"Som i Sverige bør den danske regering anerkende den vigtige rolle, disse skadesreducerede nikotinprodukter spiller i at hjælpe rygere med at overgå fra røgtobak og gøre sikrere alternativer tilgængelige, acceptable og til at betale."

Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20241006970721/da/

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Roquette Highlights Scalable Excipient and Capsule Solutions for Regional and Global Pharmaceutical Markets at CPHI India 202612.11.2026 16:00:00 CET | Press release

Helping pharmaceutical manufacturers accelerate the journey from formulation to market through deep technical expertise, meaningful innovation, close collaboration and global capabilities Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, will showcase its comprehensive portfolio of excipient and capsule solutions at CPHI India 2026, Hall 1, Booth 1I12 from November 23 to 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112803410/en/ Meet Roquette at CPHI India 2026, Hall 1, Booth 1I12 At the event, Roquette will demonstrate how it helps pharmaceutical manufacturers accelerate the journey from formulation to market with confidence. By combining technical expertise, trusted quality, meaningful innovation and close collaboration, Roquette helps customers address formulation, scale-up and manufacturing challenges across a broad range of pharmaceutical application

Tigo Energy and Google Cloud Pair AI-Powered Tools for Solar Installers and Utilities12.11.2026 15:00:00 CET | Press release

The collaboration combines Tigo software with Google’s Gemini models on Google Cloud to help automate installer and utility operations for distributed energy portfolios. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced a collaboration with Google Cloud to develop AI-enabled operational workflows for solar installers and distributed energy portfolios. By making core Tigo data and software products available through Google Cloud, Tigo aims to deliver faster deployment, simplified data integration, and additional insights with Gemini. The resulting workflows will help installers, asset managers, and energy operators more easily identify issues, prioritize actions, and automate routine operational tasks across growing fleets of distributed energy systems. As solar and storage portfolios expand, energy businesses are increasingly responsible for managing more sites, more system data, and more custo

Patsnap Releases State of Pharma Intelligence 2026 Report, Reveals Pharma's Cautious Embrace of AI in Decision-Making12.11.2026 15:00:00 CET | Press release

A new survey of 130 senior life sciences leaders on AI in pharma R&D and competitive intelligence finds that 92% can name a recent R&D, portfolio, or partnership decision where AI changed the outcome. Patsnap, the AI-native innovation intelligence company for IP and R&D teams, today released "State of Pharma Intelligence 2026: The Confidence to Act", a benchmark report on how pharma teams use and trust AI in R&D, competitive intelligence and business development decisions. The report draws on responses from 130 senior leaders at Director level or above across the United States, the United Kingdom, Germany, Switzerland, and France, spanning drug developers, CDMOs/CMOs, CROs, and consulting and professional services firms. The survey was fielded in August 2026 in partnership with NewtonX. Patsnap commissioned the research to understand how AI is influencing decisions across pharma R&D and business development, what builds confidence in its output, and where intelligence workflows fall sh

REPLY: the Board of Directors Approves the Quarterly Financial Report as of 30 September 202612.11.2026 14:41:00 CET | Press release

All economic indicators have substantially improved:Consolidated turnover of €1,987.9 million (1,819.8 as at 30 September 2025)EBITDA of €354.9 million (335.5 as at 30 September 2025)EBIT of €286.7 million (281.0 as at 30 September 2025)Pre-tax profit of €291.6 million (268.1 as at 30 September 2025)Positive Net Financial Position of €397.0 million. Today, the Board of Directors of Reply [EXM, STAR: REY] approved the results as at 30 September 2026. The Group's consolidated turnover in the first nine months of the year reached €1,987.9 million, an increase of 9.2% compared to €1,819.8 million recorded on 30 September 2025. The indicators for the period are positive. Consolidated EBITDA was €354.9 million, equal to 17.9% of the consolidated revenues. As of September 2025 EBITDA was €335.5 million. EBIT, from January to September, reached €286.7 million, equal to 14.4% of the consolidated revenues. The corresponding 2025 figure was €281.0 million. Pre-tax profit, from January to Septembe

Klarna Names Chris Koegel as Chief Financial Officer12.11.2026 14:30:00 CET | Press release

Klarna Group plc (NYSE: KLAR), the everyday finance network, has appointed Chris Koegel as Chief Financial Officer, effective 1 January 2027, subject to regulatory approval. The appointment has been approved and endorsed by the Klarna Group plc board. He will succeed Niclas Neglén, who will remain CFO until the end of 2026. Koegel joins from Robinhood Markets Inc. (NASDAQ: HOOD), where he is Vice President, Head of Corporate Finance and Investor Relations. He joined Robinhood in 2022 and has served on the Leadership Team through a period of significant growth; the company’s valuation has grown from less than $10bn and has exceeded $100bn during his tenure. Before Robinhood, he was Head of Investor Relations at LPL Financial LLC (NASDAQ: LPLA) from 2015 to 2022, after spending 13 years at Bain & Company. Koegel has a BA in Mathematics from Williams College, an MBA from Dartmouth College, and is based in the US in the Boston, MA area. “Chris’s experience as a Finance leader at a US-liste

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye